Celtaxsys Raises $45M For Novel Anti-inflammatory CF Drug Phase 2 Research
The lead drug candidate under development by Celtaxsys — an Atlanta, Georgia based clinical-stage development company focused on novel therapeutics for treating inflammatory disease through regulation of immune cell migration and activation — is CTX-4430, described as a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor that shows promise as…